YBSW-015

N/A

Report date: 2026/02/06 09:27:35

Base Information

Drug NameYBSW-015

Drug Alias NameYBSW-015

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionSARS-CoV-2 Spike glycoprotein receptor binding domain antagonists

TargetsSARS-CoV-2 Spike glycoprotein receptor binding domain

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesYabao Pharmaceutical Group Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesYabao Pharmaceutical Group Co Ltd

Active IndicationsN/A

Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A